October 2, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), in
conformity with DTR 5.6 of the FCA's Disclosure and Transparency Rules, notifies the market that as at 30 September 2017, the
issued ordinary share capital of the Company consisted of 105,017,401 ordinary shares with voting rights attached (one vote per
ordinary share). There are no ordinary shares held in treasury.
The above total voting rights figure may be used by shareholders as the denominator for the
calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in,
the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Verona Pharma plc
Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Verona Pharma plc via Globenewswire